Chemotherapy for Adult Low-grade Gliomas: Clinical Outcomes by Molecular Subtype in a Phase II Study of Adjuvant Temozolomide
Overview
Authors
Affiliations
Background: Optimal adjuvant management of adult low-grade gliomas is controversial. Recently described tumor classification based on molecular subtype has the potential to individualize adjuvant therapy but has not yet been evaluated as part of a prospective trial.
Methods: Patients aged 18 or older with newly diagnosed World Health Organization grade II low-grade gliomas and gross residual disease after surgical resection were enrolled in the study. Patients received monthly cycles of temozolomide for up to 1 year or until disease progression. For patients with available tissue, molecular subtype was assessed based upon 1p/19q codeletion and isocitrate dehydrogenase-1 R132H mutation status. The primary outcome was radiographic response rate; secondary outcomes included progression-free survival (PFS) and overall survival (OS).
Results: One hundred twenty patients were enrolled with median follow-up of 7.5 years. Overall response rate was 6%, with median PFS and OS of 4.2 and 9.7 years, respectively. Molecular subtype was associated with rate of disease progression during treatment (P<.001), PFS (P=.007), and OS (P<.001). Patients with 1p/19q codeletion demonstrated a 0% risk of progression during treatment. In an exploratory analysis, pretreatment lesion volume was associated with both PFS (P<.001) and OS (P<.001).
Conclusions: While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy. Patients with 1p/19q codeletion are potential candidates for omission of adjuvant radiotherapy, but further work is needed to directly compare chemotherapy with combined modality therapy.
Zhou Y, Jia P, Fang Y, Zhu W, Gong Y, Fan T Front Pharmacol. 2024; 15:1437436.
PMID: 39246656 PMC: 11377320. DOI: 10.3389/fphar.2024.1437436.
Darlix A, Monnier M, Castan F, Coutant L, Fabbro M, Denis-Chammas E Neurooncol Adv. 2024; 6(1):vdae084.
PMID: 38946878 PMC: 11212068. DOI: 10.1093/noajnl/vdae084.
IDH inhibition in gliomas: from preclinical models to clinical trials.
Ruda R, Horbinski C, van den Bent M, Preusser M, Soffietti R Nat Rev Neurol. 2024; 20(7):395-407.
PMID: 38760442 DOI: 10.1038/s41582-024-00967-7.
Ng S, Duffau H Cancers (Basel). 2023; 15(14).
PMID: 37509359 PMC: 10378506. DOI: 10.3390/cancers15143698.
Wu P, Filley A, Miller M, Bruce J Adv Exp Med Biol. 2023; 1405:31-71.
PMID: 37452934 DOI: 10.1007/978-3-031-23705-8_2.